BioNTech looks to Biotheus again, this time for bispecific-ADC combo


German biotech’s second deal with Biotheus marks its fifth in-licensing agreement this year with a Chinese biotech

By Danielle Golovin, Biopharma Analyst

November 8, 2023 1:46 AM UTC

Via its fifth disclosed in-licensing deal with a China biotech this year, BioNTech gains a bispecific from Biotheus that the German biotech believes will synergize with its antibody-drug conjugates.

Biotheus Inc. announced Monday it entered into a partnership with  BioNTech SE (NASDAQ:BNTX) to develop and commercialize bispecific mAb PM8002. The deal came soon after Biotheus CBO Jun Bao told BioCentury the company was eager to partner its Phase II programs, especially outside of China…